name: VIEW 2q8 Fixed Dosing - Improved
version: '2.0'
created_date: '2025-01-26'
author: Calibration Team
description: Fixed dosing protocol based on VIEW trials with improved parameters to
  match clinical outcomes
protocol_type: fixed_interval
min_interval_days: 56
max_interval_days: 112
extension_days: 0
shortening_days: 0
loading_phase:
  enabled: true
  doses: 3
  interval_days: 28
disease_transitions:
  NAIVE:
    NAIVE: 0.0
    STABLE: 0.55
    ACTIVE: 0.4
    HIGHLY_ACTIVE: 0.05
  STABLE:
    NAIVE: 0.0
    STABLE: 0.9
    ACTIVE: 0.1
    HIGHLY_ACTIVE: 0.0
  ACTIVE:
    NAIVE: 0.0
    STABLE: 0.45
    ACTIVE: 0.5
    HIGHLY_ACTIVE: 0.05
  HIGHLY_ACTIVE:
    NAIVE: 0.0
    STABLE: 0.1
    ACTIVE: 0.3
    HIGHLY_ACTIVE: 0.6
treatment_effect_on_transitions:
  NAIVE:
    multipliers: {}
  STABLE:
    multipliers:
      STABLE: 1.2
      ACTIVE: 0.8
  ACTIVE:
    multipliers:
      STABLE: 3.0
      ACTIVE: 0.6
      HIGHLY_ACTIVE: 0.2
  HIGHLY_ACTIVE:
    multipliers:
      STABLE: 2.0
      ACTIVE: 1.8
      HIGHLY_ACTIVE: 0.6
vision_change_model:
  naive_treated:
    mean: 4.5
    std: 2
  naive_untreated:
    mean: -3
    std: 2
  stable_treated:
    mean: 2.5
    std: 1.5
  stable_untreated:
    mean: -0.5
    std: 1
  active_treated:
    mean: 1.5
    std: 2
  active_untreated:
    mean: -3
    std: 2
  highly_active_treated:
    mean: 0.5
    std: 2
  highly_active_untreated:
    mean: -5
    std: 3
baseline_vision_distribution:
  type: normal
  mean: 53.7
  std: 13.4
  min: 20
  max: 85
discontinuation_rules:
  poor_vision_threshold: 20
  poor_vision_probability: 0.02
  high_injection_count: 999
  high_injection_probability: 0.0
  long_treatment_months: 24
  long_treatment_probability: 0.005
  discontinuation_types:
  - planned
  - adverse
  - ineffective
clinical_improvements:
  enabled: true
  use_loading_phase: true
  use_time_based_discontinuation: false
  use_response_based_vision: true
  use_baseline_distribution: false
  use_response_heterogeneity: true
  response_types:
    good:
      probability: 0.31
      multiplier: 2.5
    average:
      probability: 0.64
      multiplier: 1.5
    poor:
      probability: 0.05
      multiplier: 0.5
  discontinuation_probabilities:
    1: 0.125
    2: 0.15
    3: 0.12
    4: 0.08
    5: 0.075
target_outcomes:
  year1:
    mean_bcva_change: 8.4
    vision_maintenance_rate: 0.954
    gainers_15_plus_rate: 0.31
    mean_injections: 7.5
  year2:
    mean_injections: 11.2
